Keyword: Intercept Pharmaceuticals
Arcturus Therapeutics and its ousted CEO Joseph Payne agreed to end litigation against each other.
Arcturus is losing its second executive in as many weeks: CSO/COO Pad Chivukula, who will take an advisory role.
Metacrine is adding to this week's NASH talk after getting off a series B as it aims to combat the fatty liver disorder.
In new phase 2 data published today, Gilead says a higher dose of its NASH drug saw statistically significant reductions in liver fat.
The cash injection will also position Genfit to look to life beyond the phase 3 by supporting commercial preparations and the in-licensing of assets.
French biotech Genfit, a leader in the race to sell a new med for fatty liver disease, said in its financials that it will delay its phase 3 NASH trial in patients with liver scarring by four to six months.
A phase 2 trial of Bristol-Myers' NASH candidate BMS-986036 met its primary endpoint.
Frazier Healthcare Partners has once again installed a trio of biotech veterans at the helm and put up cash to get through a vital trial.
Inventiva has raised €48 million through an IPO to take its lead candidate through phase 2b trials in NASH and systemic sclerosis.
Intercept was down 12% premarket this morning as it announced an out-of-the-blue update on its late-stage fatty liver disease test, but jumped first thing after changing its endpoints and the definition of NASH improvement for its study.